mitomycin has been researched along with Chemical and Drug Induced Liver Injury in 10 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As adverse reactions to the combination treatment by the digestive system, we observed the occurrence of nausea and vomiting in 15% of the cases who received FTP treatment consisting of 5-FU, toyomicin and prednisone, 25% of the cases who received MFU treatment consisting of MMC, 5-FU and ACNU, and in 64% of the cases who received PPQ treatment consisting of CDDP, Carboquone (CQ) and prednisone." | 3.67 | [Adverse reactions to carcinostatics and countermeasures]. ( Nakao, I, 1989) |
| "5 mg/kg of mitomycin-C (Mit-C) resulted in 70% (n = 20) and 71% (n = 14) mortality, respectively, from 2 to 7 days after perfusion, with extensive, patchy necrosis and infarction seen on histologic examination and markedly elevated levels of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) at 6 and 24 hours after perfusion." | 3.66 | Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol. ( Falk, JA; Falk, RE; Falk, W; Makowka, L; Miyazaki, M; Venturi, D, 1983) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " Pharmacokinetic studies using HPLC technique were done in nine patients." | 1.27 | High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhematopoietic toxicities. ( Baker, LH; Emmer, D; Hoschner, JA; Karanes, C; Leichman, L; Ratanatharathorn, V; Schilcher, RB; Young, JD, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Rjiba-Touati, K | 1 |
| Ayed-Boussema, I | 1 |
| Belarbia, A | 1 |
| Mokni, M | 1 |
| Achour, A | 1 |
| Bacha, H | 1 |
| Abid, S | 1 |
| Miyazaki, M | 1 |
| Makowka, L | 1 |
| Falk, RE | 1 |
| Falk, JA | 1 |
| Falk, W | 1 |
| Venturi, D | 1 |
| Schlangen, J | 1 |
| Wils, J | 1 |
| Nakao, I | 1 |
| Karanes, C | 1 |
| Ratanatharathorn, V | 1 |
| Schilcher, RB | 1 |
| Young, JD | 1 |
| Emmer, D | 1 |
| Hoschner, JA | 1 |
| Leichman, L | 1 |
| Baker, LH | 1 |
1 review available for mitomycin and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
9 other studies available for mitomycin and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Role of recombinant human erythropoietin against mitomycin C-induced cardiac, hepatic and renal dysfunction in Wistar rats.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Chemical and Drug Induced Liver Injury; Drug A | 2015 |
Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol.
Topics: Acute Disease; Animals; Chemical and Drug Induced Liver Injury; Cytosol; Fluorouracil; Hyperthermia, | 1983 |
Liver calcifications following hepatic artery infusion with 5-fluorouracil, adriamycin and mitomycin C (FAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Chemical and Drug Induced Liver Injury; | 1984 |
[Adverse reactions to carcinostatics and countermeasures].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Chemical and Drug Indu | 1989 |
High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhematopoietic toxicities.
Topics: Adult; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Com | 1986 |